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Background: Clostridium difficile infection (CDI) is the leading cause of infectious noso-
comial diarrhoea in Europe. Despite increased focus, its incidence and severity are
increasing in many European countries.
Aim: We developed a series of consensus statements to identify unmet clinical needs in
the recognition and management of CDI.
Methods: A consortium of European experts prepared a series of 29 statements repre-
senting their collective views on the diagnosis and management of CDI in Europe. The
statements were grouped into the following six broad themes: diagnosis; definitions of
severity; treatment failure, recurrence and its consequences; infection prevention and
control interventions; education and antimicrobial stewardship; and National CDI clinical
guidance and policy. These statements were reviewed using questionnaires by 1047 clin-
icians involved in managing CDI, who indicated their level of agreement with each
statement.
Findings: Levels of agreement exceeded the 66% threshold for consensus for 27 out of 29
statements (93.1%), indicating strong support. Variance between countries and specialties
was analysed and showed strong alignment with the overall consensus scores.Clinical Infection and Diagnostics Research, Guy’s & St Thomas’ NHS Foundation Trust, Westminster
(0) 20 7188 8515; fax: þ44 (0) 20 7188 3146.
s.uk (S.D. Goldenberg).
lsevier Ltd on behalf of the Healthcare Infection Society. This is an open access article under the CC
rg/licenses/by-nc-nd/4.0/).
J.M. Aguado et al. / Journal of Hospital Infection 90 (2015) 117e125118Conclusion: Based on the consensus scores of the respondent group, recommendations are
suggested for the further development of CDI services in order to reduce transmission and
recurrence and to ensure that appropriate diagnosis and treatment strategies are applied
across all healthcare settings.
ª 2015 The Authors. Published by Elsevier Ltd on behalf of the Healthcare Infection
Society. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Clostridium difficile is the leading cause of infectious
nosocomial bacterial diarrhoea in industrialized countries.1
The incidence and severity of C. difficile infection (CDI) is
increasing in most countries and is associated with significant
morbidity and mortality.2 This represents a large clinical
burden due to resultant severe diarrhoea and potential com-
plications, including pseudomembranous colitis, toxic mega-
colon, colonic perforation and sepsis.3,4 Recognized risk factors
for disease include antimicrobial therapy, advanced age,
treatment with proton pump inhibitors and immunological non-
responsiveness to CDI.5 From a patient perspective, CDI is
associated with impaired quality of life.6 In addition, there is
an association with prolonged hospitalization and increased
healthcare costs, making CDI an increasingly important public
health issue.6e11
The European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) has highlighted recurrence as the most
important issue in the management of CDI.12 Up to 25% of pa-
tients suffer a recurrence of infection within 30 days following
treatment.13e15 For patients who have already experienced
one recurrence, the risk of further recurrence is estimated to
be between 40% and 60%.16,17 Recurrent CDI is a difficult-to-
treat problem, with an impact on both length of stay and
hospitalization costs, particularly in patients with immuno-
suppression, renal impairment or who are aged65 years.18e20
Reducing recurrences could potentially reduce the clinical
burden, reduce the economic impact of treating additional
episodes, and limit spread by onward transmission.
Although uncomplicated cases of CDI have traditionally
been treated with metronidazole or oral vancomycin, recent
reports suggest that CDI is becoming increasingly difficult to
treat.21e23 Patients with hospital-associated CDI have a 30-day
attributable mortality between 3% and 30%.15 Surgical thera-
pies such as total colectomy are required in 3e5% of fulminant
CDI cases and are associated with mortality rates ranging from
34% to 80%.24e28 Many patients with CDI are already vulnerable
due to comorbidities; hospitalized patients with CDI are up to
three times more likely than those without CDI to die in hos-
pital or within 30 days of admission.12
The clinical burden of managing primary cases and re-
currences, together with associated management such as
cleaning and decontamination, contribute to significant eco-
nomic costs. US studies estimate the economic burden of CDI to
vary between $2,450 and $40,000 per episode.10 A substantial
element of the additional cost relates to the accommodation
costs resulting from a prolonged hospital stay. A systematic
review of costs related to CDI in Europe found that incremental
costs ranged from £4,577 in Ireland to £8,843 in Germany.29 A
German study showed a median cost of treating CDI of V33,840
per patient, an increase of V7,147 over non-infected matchedcontrol cases.30 Overall the cost of CDI is estimated at V3
billion per year in the EU and there is concern that this will rise
as the population aged >65 years increases.2
We sought to identify a set of consensus views representing
a range of healthcare professionals across Europe. In partic-
ular, the attitudes and perceived unmet clinical needs
regarding CDI were solicited. The process explored the re-
actions of a wide group of respondents to the consensus
statements devised by this group, allowing comparison of at-
titudes and views from different national perspectives across
Europe.Methods
Astellas Pharma EMEA initiated and fully supported the
consensus project including the selection of the initial faculty
of experts, who were able to cover the broad aspects of CDI
management. Astellas Pharma EMEA commissioned Triducive
Ltd to facilitate the project and analyse the responses to the
consensus statements, in line with the Delphi methodology.
Astellas Pharma EMEA provided editorial assistance for the final
manuscript by way of a factual accuracy check only. The author
group, led by Dr S. Goldenberg, has jointly prepared the
manuscript.
An international group of ten physicians including micro-
biologists, gastroenterologists, infectious diseases and inten-
sive care physicians experienced in the management of CDI,
were invited by Astellas Pharma EMEA to meet in Autumn 2013
with the objective of defining themes for future developments
in the management of CDI. The ideas developed by the group
were not restricted and the following broad themes emerged:
e Diagnosis of CDI
e Definitions of severity
e Treatment failure, recurrence and its consequences
e Infection prevention and control interventions across all
care settings
e Education and antimicrobial stewardship
e National CDI clinical guidance and policy.
Discussion around each of these themes generated a set of
29 consensus statements. Whereas the group developed the
initial consensus statements, the involvement of a wider
audience reflecting the views of key stakeholders across
Europe is essential in order to develop a robust consensus.
Therefore, the statements were circulated by questionnaire
across Europe in order to test levels of agreement. Question-
naires were sent to healthcare professionals across specialties
reflecting the roles of the steering group. The questionnaires
were circulated to personal contacts of the steering group, by
contacts of Astellas sales representatives, through e-mail dis-
tribution lists of professional societies with an interest in
Table I
Respondent roles
Respondent specialty/professional group N (%)
Intensive care 240 (22.9)
Infectious diseases 224 (21.4)
Internal medicine 164 (15.7)
Microbiology 117 (11.2)
Unknown role/anonymous 94 (9)
GI medicine/gastroenterology 87 (8.3)
Haematology/oncology 66 (6.3)
Geriatrics 19 (1.8)
Pharmacy 16 (1.5)
Transplant surgery 16 (1.5)
Palliative care 4 (0.4)
Total 1047
GI, gastrointestinal.
Table II
Respondents by country
Country N (%)
Germany 427 (40.8)
Italy 166 (15.9)
Spain 137 (13.1)
Sweden 99 (9.4)
France 98 (9.4)
UK 64 (6.1)
Austria 38 (3.6)
Finland 18 (1.7)
Total 1047
J.M. Aguado et al. / Journal of Hospital Infection 90 (2015) 117e125 119infection and at infectious diseases medical conferences. In all
countries except Spain, the questionnaires were written in
English.
In order to achieve consensus with the wider group, a Delphi
methodology was used.31 The Delphi method works through
written feedback, in order to measure consensus or agreement
where differing opinions may exist. The level of individual1 2 3 4 5 6 7 8 9 10 11 12 13 14
Stateme
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Figure 1. Total consensuagreement with each statement is measured using a four-point
Likert scale, which allows respondents to record levels of
agreement with each statement and suggest changes as
appropriate. The four-point Likert scale forces either agree-
ment or disagreement with each statement (strongly disagree,
disagree, agree, or strongly agree).
Following review of the responses as numbers increased, the
process allows the modification of each statement if necessary
in order to increase the level of agreement and therefore
represent the majority view of respondents.Results
A total of 1047 respondents completed questionnaires
within Europe, distributed across a variety of professional roles
(Table I). The greatest number of respondents was from
intensive care (22.9%, N¼ 240), followed by infectious diseases
(21.4%, N ¼ 224), internal medicine (15.7%, N ¼ 164), and
microbiology (11.2%, N ¼ 117).
Respondents were distributed across Europe by country
(Table II). The majority of respondents were from Germany
(40.8%, N ¼ 427), followed by Italy (15.9%, N ¼ 166) and Spain
(13.1%, N ¼ 137).
The Consensus Group predefined the threshold of agree-
ment for consensus to be 66%. Consensus was defined as
‘high’ at>66% and as ‘very high’ at>90%. Only two statements
failed to meet this criterion: in all, 27 of the 29 statements
(93.1%) achieved agreement scores of >66%. Statement 4
scored 65.2% and statement 12 scored 60.1% (Figure 1). In to-
tal, 20 of the statements achieved very high consensus, >90%.
Individual scores for each statement are shown in Table III.
Although some variance was seen between different coun-
tries (Figure 2), the pattern of country responses is well aligned
with the overall consensus scores. As with the overall analysis,
statement 4 achieved the lowest levels of agreement in all
countries, with statement 8 scoring low in Sweden, France, and
the UK and statement 12 achieving lowest consensus in Swe-
den, Spain, France, and Germany. Statement 12 showed the
greatest variance between countries as the UK score of 91.9%
agreement is markedly different from that of other countries.nt number
15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
s agreement scores.
Table III
Individual agreement scores by statement
Theme Statement Overall agreement
Diagnosis of CDI (at-risk patient considerations) 1. Clostridium difficile testing should be performed on all stools from patients presenting
with healthcare-associated diarrhoea
91.0%
2. Clearly defined clinical algorithms should be implemented for stool specimen collection
in all European countries
93.5%
3. The optimal method for laboratory diagnosis of CDI is a two-stage algorithm that
incorporates a test for GDH (or a NAAT) followed by a toxin EIA
88.3%
4. The role of colonoscopy/sigmoidoscopy should be further defined as part of the
diagnostic work-up for CDI
65.9%
Defining severe vs non-severe CDI 5. Criteria for defining severity of CDI vary between existing guidelines and have not yet
been fully characterized and validated
86.9%
6. CDI is a potentially life-threatening infection and therefore patients with severe CDI
should be monitored intensively
94.2%
7. CDI treatment should be guided by diagnosis and by the patient’s underlying condition
and comorbidities
97.4%
8. Mortality rates do not correlate with the current definitions of severe vs non-severe CDI 70.1%
Guidance on how to respond to treatment
failure and CDI recurrence
9. A better understanding of the reasons for treatment failure is needed to improve
CDI management
94.9%
10. More evidence is needed to inform treatment strategies for CDI treatment failure 92.1%
11. A validated measure of treatment responsiveness is required based on biomarkers/
clinical parameters
86.6%
12. For patients with severe CDI who are failing treatment; to reflect the decision-making
process while a severely ill patient is on therapy and not responding, surgical
treatment should be actively considered at an early stage
60.7%
Consequences of CDI recurrence 13. Patients’ underlying comorbidities are a predictor for increased mortality with CDI 96.1%
14. Recurrent CDI is a strong contributor to poor clinical outcomes, increased length of
hospital stay and increased costs
97.3%
15. Treatment decisions for both initial infection and recurrent CDI should take into
account the impact on resource utilization and wider societal costs
90.7%
16. There are certain patients, e.g. those receiving concomitant antibiotics,
immunosuppressants, oncologic treatments, post surgery, who are at high risk of
serious clinical consequences of recurrent CDI
97.5%
17. Awareness of the recurrent nature of CDI should be recognized and consistent long-term
follow-up of CDI patients is desirable
89.8%
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Infection control measures for CDI in care
settings (cost and resource management)
18. Infection control should be a priority at all levels of healthcare management, including
facility design ensuring sufficient resources are made available for consistent and
sufficient decontamination
96.5%
19. Awareness of the signs and symptoms of CDI need to be increased across all
healthcare professionals to drive improved testing and diagnosis and all patients
with diarrhoea should be treated with contact precautions until proven non-infectious
90.1%
20 Improving compliance with appropriate infection control measures is crucial in
preventing transmission of C. difficile including the practice of hand hygiene by
healthcare professionals, patients, and relatives using soap and water
97.4%
21. Sufficient isolation facilities, meeting consistent defined standards, should be available
for all patients with CDI or suspected CDI in all healthcare facilities
93.2%
Education and antibiotic stewardship 22. Managers of all healthcare systems and institutions should assign a high priority to
CDI to drive educational programmes targeting all healthcare practitioners
91.1%
23. Improved co-operation between hospitals, nursing homes and community healthcare
is necessary to increase awareness of CDI and ultimately improve diagnosis, treatment
and prevention
94.3%
24. Antibiotic stewardship needs to be implemented in all institutions to ensure effective
use of antimicrobials and to educate healthcare professionals on the impact of
antibiotic prescribing and the consequences of treating CDI
96.0%
25. Antibiotics should not be prescribed without the approval of a professional specifically
trained in antimicrobial prescribing
72.6%
National CDI policy 26. National policy for CDI should reflect the evidence base and offer a framework for
implementation of national CDI guidelines at all levels of healthcare provision
94.4%
27. National CDI policy should aim to ensure consistent prevention, diagnosis and treatment
of CDI in all healthcare settings
96.9%
28. Standardized and transparent reporting of CDI should be adopted nationally to ensure
comparability of epidemiological data
92.2%
29. Europe-wide harmonization of CDI data collection and reporting is desirable 89.5%
CDI, Clostridium difficile infection; GDH, glutamate dehydrogenase; NAAT, nucleic acid amplification test; EIA, enzyme immunoassay.
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Figure 2. Consensus agreement scores by country.
J.M. Aguado et al. / Journal of Hospital Infection 90 (2015) 117e125122The responses are also well aligned when analysed by spe-
cialty with internal medicine, yielding the lowest agreement
scores and microbiology the highest (Figure 3).
Overall, high levels of agreement with 27 of the 29 state-
ments suggest that consensus is strong, with little variation
between countries or specialties.
Discussion
Diagnosis of CDI
Overall agreement with the statements concerning diagnosis
of CDI is high (>66%) or very high (>90%) with the exception of100.0%
90.0%
80.0%
70.0%
60.0%
50.0%
40.0%
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Stateme
0
Microbiology GI Infectious Dise
Figure 3. Consensus agreemstatement 4 (65.9%). The same pattern is seen across countries
and specialties. Respondents strongly agree that:
e C. difficile testing should be performed on all stools from
patients presenting with healthcare-associated diarrhoea
(91.0%);
e clearly defined clinical algorithms should be implemented
for stool specimen collection in all European countries
(93.5%);
e the optimal method for laboratory diagnosis of CDI is a two-
stage algorithm that incorporates a test for glutamate de-
hydrogenase (or a nucleic acid amplification test) followed
by a toxin enzyme immunoassay (88.3%).nt number
15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
ase Internal Medicine Haematology / Oncology
ent scores by specialty.
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sigmoidoscopy within the diagnostic work-up, achieved the
lowest score of all of the statements (65.9% agreement) and
failed to meet the consensus threshold of >66%. Presumably,
the phrasing of the statement is too ambiguous to give a
conclusive response. Whereas it is clear that most respondents
support further definition of the role of colonoscopy and
sigmoidoscopy, the low agreement score may be due to con-
cerns that the sensitivity of endoscopy is too low to implement
into primary diagnostic algorithms for CDI.32,33 However, in
severely ill patients with acute onset of bloody diarrhoea,
endoscopic visualization of the lower gastrointestinal tract
may allow rapid exclusion of relevant differential diagnoses of
CDI. Thus, a consensus needs to be reached about which pa-
tient groups may benefit from early endoscopy for suspected
CDI.Definitions of severity
All statements within this section achieved overall agree-
ment scores of 70%. Further clarity may be needed to define
the severity of CDI, aligned with mortality data so that
appropriate treatment strategies can be applied. It should be
noted that respondents in the UK, Sweden, and France showed
lower agreement that mortality rates do not correlate with
current definitions of CDI severity (statement 8), whereas re-
spondents from Spain and Italy were more strongly supportive
of this statement, which may reflect differing epidemiology.
Overall consensus is supportive of these statements.Treatment failure, recurrence and their consequences
Agreement with statements 9 and 10 exceeding 90% in-
dicates a call from respondents for clarity regarding reasons for
treatment failure and the definition of appropriate strategies
for managing patients in whom treatment has failed. There is
also strong support (86.3%) for a validated measure of treat-
ment response.
Statement 12 achieved the lowest score overall (60.7%),
suggesting that respondents are less supportive of considering
surgery at an early stage. However, when examined by country,
it is clear that respondents from the UK agreed more strongly
than those from other countries. This may suggest that a lack of
clarity in the wording of the statement contributed to lower
levels of agreement or that the UK experiences more severe
cases, with a need for surgical intervention. When examined by
specialty, responses are more closely aligned.
Respondents also agreed that:
e patients’ underlying comorbidities are a predictor for
increased mortality with CDI (96.1%);
e recurrent CDI is a strong contributor to poor clinical out-
comes, increased length of hospital stay and increased
costs (97.3%);
e treatment decisions should take into account impacts on
resource use and wider societal costs (90.7%);
e there are certain patients, e.g. those receiving concomi-
tant antibiotics, immunosuppressants, oncologic treat-
ments, post surgery, who are at high risk of serious clinical
consequences of recurrent CDI (97.5%);e awareness of the recurrent nature of CDI should be
recognized and consistent long-term follow-up of CDI pa-
tients is desirable (89.8%).Control of infection for CDI across care settings
High overall agreement scores >90% for all statements in
this category reflect strong support for the need to prioritize
infection control measures in all care settings. Respondents
strongly agree that:
e infection control should be a priority at all levels of
healthcare management, including facility design, to
ensure that sufficient resources are made available for
consistent and sufficient decontamination (96.5%);
e awareness of the signs and symptoms of CDI need to be
increased across all healthcare professionals to drive
improved testing and diagnosis and all patients with diar-
rhoea should be treated with contact precautions until
proven non-infectious (90.1%);
e improving compliance with appropriate infection control
measures is crucial in preventing transmission of
C. difficile, including the practice of hand hygiene by
healthcare professionals, patients, and relatives using soap
and water (97.4%);
e sufficient isolation facilities that meet consistent defined
standards should be available for all patients with CDI or
suspected CDI in all healthcare facilities (93.2%).Education and antibiotic stewardship
Strong overall support for statement 24 (96.0%) indicates
that respondents agree with the need for antibiotic steward-
ship measures to be implemented in all institutions to ensure
effective use of antimicrobials and to educate healthcare
professionals on the impact of antibiotic prescribing and the
consequences of treating CDI. Whereas consensus was clearly
achieved for statement 25 (72.6%), it is clear that fewer re-
spondents are comfortable with more direct control methods
for the prescribing of antibiotics. This consensus is well aligned
across specialties, but less so between countries.
Respondents from Italy and Spain were more accepting of
antibiotic prescribing being limited to specifically trained
professionals, than were those from Germany, the UK, Sweden,
and France. This may be because of an increased awareness of
the need to limit antibiotic prescribing in Italy and Spain
following the recent ECDC report, which showed that Italy and
Spain had the highest antimicrobial use of the countries
observed.34National CDI policy
All statements in this category achieved high levels of
overall agreement (>89.4%) and were well aligned by country
and specialty. Respondents strongly agreed that:
e national policy for CDI should reflect the evidence base and
offer a framework for implementation of national CDI
guidelines at all levels of healthcare (94.4%);
J.M. Aguado et al. / Journal of Hospital Infection 90 (2015) 117e125124e national CDI policy should aim to ensure consistent pre-
vention, diagnosis, and treatment of CDI in all healthcare
settings (96.9%);
e standardized and transparent reporting of CDI should be
adopted nationally to ensure comparability of epidemio-
logical data (92.2%);
e Europe-wide harmonization of CDI data collection and
reporting is desirable (89.5%).
There are several limitations to this study. First, the study
captured the views of a limited group of specialists mostly
within infectious diseases, microbiology, intensive care, and
internal medicine. The methods employed to collect the data
meant that there was a much stronger focus on these spe-
cialties and that other groups are under-represented (e.g.
geriatrics) or omitted completely (e.g. general or gastrointes-
tinal surgery). Similarly, the study focused on Western Euro-
pean countries only, so is not representative of opinions and
practice of clinicians in Eastern Europe.
In conclusion, the high levels of consensus achieved from
the 1047 respondents across eight European countries suggest
that issues relating to the management of CDI are well under-
stood by clinical professionals. These statements are offered as
suggested standards, and those responsible for the manage-
ment of hospital-acquired infection including CDI may find
them useful in assessing their alignment with them. An un-
derstanding of the actual variance between these standards
and common clinical practice may support further improve-
ment of CDI treatment and the management of recurrent
cases.
Additional research is required in a number of areas
including parameters to differentiate between severe and mild
CDI. In addition, clearer guidance regarding predictors for CDI
and recurrence will assist in defining optimal case management
approaches. Societal and community impacts of CDI are not
well described and also require further investigation.
The role of surgery in managing severe CDI and the value of
colonoscopy and sigmoidoscopy in diagnosis require clarifica-
tion. The correlation between mortality rates and current
definitions of severe and non-severe CDI is poorly defined and
respondent attitudes show some variance across European
countries. This may lead to inequity of care provision and effort
should be made to encourage hospitals to report incidence data
clearly and ensure that they are either reaching infection
control targets or are on clear trajectory to achieving them.
This group offers the following recommendations for the
future management of CDI:
1. Definitions for the severity of CDI need to be more robust.
In particular, a meta-analysis of the literature is needed to
identify definitions of severe and non-severe CDI. This will
simplify and clarify appropriate reporting of cases.
2. Clearly defined clinical algorithms for stool specimen se-
lection, collection, and testing should be implemented in
all European countries.
3. We must better define how optimal CDI treatment can be
planned for patients receiving concomitant antibiotics,
immunosuppressants, oncologic treatments and those who
have had recent surgery or have other risk factors such as
PPI use.
4. Infection control interventions are critical in the manage-
ment of CDI and they should be resourced appropriatelyand applied robustly to ensure that transmission of CDI is
limited.
5. Hospitals and community-based health and social care
services should collaborate to increase awareness of CDI
and ultimately improve prevention, diagnosis and
treatment.
6. Antibiotic stewardship should be improved in all healthcare
institutions and should include education for all healthcare
professionals, particularly in countries with recognized
high use of antimicrobials.
7. National policies should seek to ensure consistent surveil-
lance, prevention, diagnosis, and treatment of CDI in all
healthcare settings.
In addition, it is hoped that this work will allow us to un-
derstand attitudes to guidance within Europe and provide a
platform for the support of proactive management of CDI.
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